Market Cap 21.50M
Revenue (ttm) 140,000.00
Net Income (ttm) -24.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -17,735.71%
Debt to Equity Ratio 0.00
Volume 964,800
Avg Vol 2,323,722
Day's Range N/A - N/A
Shares Out 34.10M
Stochastic %K 46%
Beta -1.07
Analysts Strong Sell
Price Target $2.00

Company Profile

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI)...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 427 8100
Address:
3513 Brighton Boulevard, Suite 410, Denver, United States
Aznwactrackstar
Aznwactrackstar Oct. 25 at 3:10 PM
$ICU Can someone check on Josh77? Hasnt posted since yesterday at 10:31PM.
1 · Reply
nonferrousguy
nonferrousguy Oct. 25 at 1:01 PM
$ICU Does anyone know when the earnings report will be released?
0 · Reply
CanadianDreamcast
CanadianDreamcast Oct. 25 at 7:13 AM
$ICU I lied sorry. Dude makes half a mill a year and hasn't bought one share. Let that sink in. Now I'm really done. #noschlorffinthegame
1 · Reply
CanadianDreamcast
CanadianDreamcast Oct. 25 at 3:52 AM
$ICU All 135,982 shares acquired by SeaStar Medical CEO Eric Schlorff were awarded to him, rather than purchased. SEC filings show the transactions were designated as "Grant/Award/Other Acquisition".....hasn't bought ONE SINGLE SHARE. All word No Deed. I'll quit complaining. Have a good weekend. Go Jays.
0 · Reply
josh77
josh77 Oct. 25 at 3:31 AM
$ICU What to Watch Full FDA approvals for adult indications Expanded CMS reimbursement beyond clinical trials Hospital adoption rates and real-world outcomes International expansion, especially in Europe and Asia
0 · Reply
josh77
josh77 Oct. 25 at 3:30 AM
$ICU Commercialization Strategy 🔗 Seamless Integration SCD therapy is designed to integrate directly into existing hemodialysis systems, making adoption easier for hospitals and ICUs. This reduces training and infrastructure barriers, accelerating uptake. 📦 Launch Milestones QUELIMMUNE therapy for pediatric AKI was commercially launched in July 2024, marking SeaStar’s transition to a revenue-generating company. Future launches will depend on trial outcomes and FDA approvals for adult indications like cardiorenal syndrome and systemic inflammatory response. 🤝 Strategic Partnerships SeaStar may pursue distribution partnerships with dialysis equipment providers or hospital networks to scale adoption. CMS coverage and FDA designations make it more attractive to potential collaborators.
0 · Reply
josh77
josh77 Oct. 25 at 3:30 AM
$ICU Reimbursement Outlook ✅ CMS Coverage Secured In May 2025, SeaStar received CMS (Centers for Medicare & Medicaid Services) approval to cover medical expenses for Medicare and Medicaid patients enrolled in its NEUTRALIZE-CRS trial for cardiorenal syndrome. This is a rare achievement—fewer than 100 clinical trials receive CMS coverage annually—signaling strong confidence in the therapy’s potential. 🧒 Pediatric AKI Pathway The pediatric version of SCD (QUELIMMUNE) received an Approvable Letter from the FDA in late 2023. Once fully approved, reimbursement for pediatric AKI treatment could follow quickly, especially given the Humanitarian Device Exemption (HDE) pathway, which simplifies access for rare conditions.
0 · Reply
josh77
josh77 Oct. 25 at 3:29 AM
$ICU SeaStar’s combination of strong clinical signals, regulatory momentum, and a massive market opportunity positions it as a potential disruptor in the ICU therapeutics space.
0 · Reply
josh77
josh77 Oct. 25 at 3:29 AM
$ICU SeaStar’s Edge: Mortality Impact: SeaStar’s pilot trial showed a 31% absolute reduction in mortality, which is substantial in ICU settings. Precision Immunomodulation: Targets activated neutrophils and monocytes, unlike broader cytokine filters. Pediatric Focus: QUELIMMUNE therapy fills a critical gap in pediatric AKI treatment.
0 · Reply
josh77
josh77 Oct. 25 at 3:29 AM
$ICU Clinical Trial Data Comparison Company / Therapy Key Trial Results Target Conditions Regulatory Status SeaStar Medical (SCD) 60-day mortality reduced to 50% vs 81% in control group (COVID-19 ICU trial) AKI, SIRS, COVID-19, Cardiac Surgery Multiple FDA Breakthrough Designations CytoSorbents (CytoSorb) Shown to reduce cytokine levels; mixed results on mortality in sepsis trials Sepsis, Cardiac Surgery CE Mark, FDA Emergency Use ExThera Medical (Seraph 100) Case studies show pathogen clearance; limited large-scale trial data Sepsis, COVID-19 CE Mark, FDA Emergency Use Toraymyxin Improved survival in septic shock (Japan); limited Western trial data Septic shock Approved in Japan, EU
0 · Reply
Latest News on ICU
SeaStar Medical Announces Positive Nasdaq Listing Determination

Jul 2, 2025, 4:25 PM EDT - 4 months ago

SeaStar Medical Announces Positive Nasdaq Listing Determination


SeaStar Medical Reports Update on Nasdaq Listing Status

Jun 25, 2025, 8:05 AM EDT - 4 months ago

SeaStar Medical Reports Update on Nasdaq Listing Status


NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

Mar 18, 2025, 8:45 AM EDT - 7 months ago

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award


SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

Oct 31, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE


Aznwactrackstar
Aznwactrackstar Oct. 25 at 3:10 PM
$ICU Can someone check on Josh77? Hasnt posted since yesterday at 10:31PM.
1 · Reply
nonferrousguy
nonferrousguy Oct. 25 at 1:01 PM
$ICU Does anyone know when the earnings report will be released?
0 · Reply
CanadianDreamcast
CanadianDreamcast Oct. 25 at 7:13 AM
$ICU I lied sorry. Dude makes half a mill a year and hasn't bought one share. Let that sink in. Now I'm really done. #noschlorffinthegame
1 · Reply
CanadianDreamcast
CanadianDreamcast Oct. 25 at 3:52 AM
$ICU All 135,982 shares acquired by SeaStar Medical CEO Eric Schlorff were awarded to him, rather than purchased. SEC filings show the transactions were designated as "Grant/Award/Other Acquisition".....hasn't bought ONE SINGLE SHARE. All word No Deed. I'll quit complaining. Have a good weekend. Go Jays.
0 · Reply
josh77
josh77 Oct. 25 at 3:31 AM
$ICU What to Watch Full FDA approvals for adult indications Expanded CMS reimbursement beyond clinical trials Hospital adoption rates and real-world outcomes International expansion, especially in Europe and Asia
0 · Reply
josh77
josh77 Oct. 25 at 3:30 AM
$ICU Commercialization Strategy 🔗 Seamless Integration SCD therapy is designed to integrate directly into existing hemodialysis systems, making adoption easier for hospitals and ICUs. This reduces training and infrastructure barriers, accelerating uptake. 📦 Launch Milestones QUELIMMUNE therapy for pediatric AKI was commercially launched in July 2024, marking SeaStar’s transition to a revenue-generating company. Future launches will depend on trial outcomes and FDA approvals for adult indications like cardiorenal syndrome and systemic inflammatory response. 🤝 Strategic Partnerships SeaStar may pursue distribution partnerships with dialysis equipment providers or hospital networks to scale adoption. CMS coverage and FDA designations make it more attractive to potential collaborators.
0 · Reply
josh77
josh77 Oct. 25 at 3:30 AM
$ICU Reimbursement Outlook ✅ CMS Coverage Secured In May 2025, SeaStar received CMS (Centers for Medicare & Medicaid Services) approval to cover medical expenses for Medicare and Medicaid patients enrolled in its NEUTRALIZE-CRS trial for cardiorenal syndrome. This is a rare achievement—fewer than 100 clinical trials receive CMS coverage annually—signaling strong confidence in the therapy’s potential. 🧒 Pediatric AKI Pathway The pediatric version of SCD (QUELIMMUNE) received an Approvable Letter from the FDA in late 2023. Once fully approved, reimbursement for pediatric AKI treatment could follow quickly, especially given the Humanitarian Device Exemption (HDE) pathway, which simplifies access for rare conditions.
0 · Reply
josh77
josh77 Oct. 25 at 3:29 AM
$ICU SeaStar’s combination of strong clinical signals, regulatory momentum, and a massive market opportunity positions it as a potential disruptor in the ICU therapeutics space.
0 · Reply
josh77
josh77 Oct. 25 at 3:29 AM
$ICU SeaStar’s Edge: Mortality Impact: SeaStar’s pilot trial showed a 31% absolute reduction in mortality, which is substantial in ICU settings. Precision Immunomodulation: Targets activated neutrophils and monocytes, unlike broader cytokine filters. Pediatric Focus: QUELIMMUNE therapy fills a critical gap in pediatric AKI treatment.
0 · Reply
josh77
josh77 Oct. 25 at 3:29 AM
$ICU Clinical Trial Data Comparison Company / Therapy Key Trial Results Target Conditions Regulatory Status SeaStar Medical (SCD) 60-day mortality reduced to 50% vs 81% in control group (COVID-19 ICU trial) AKI, SIRS, COVID-19, Cardiac Surgery Multiple FDA Breakthrough Designations CytoSorbents (CytoSorb) Shown to reduce cytokine levels; mixed results on mortality in sepsis trials Sepsis, Cardiac Surgery CE Mark, FDA Emergency Use ExThera Medical (Seraph 100) Case studies show pathogen clearance; limited large-scale trial data Sepsis, COVID-19 CE Mark, FDA Emergency Use Toraymyxin Improved survival in septic shock (Japan); limited Western trial data Septic shock Approved in Japan, EU
0 · Reply
josh77
josh77 Oct. 25 at 3:28 AM
$ICU Market Potential SeaStar Medical projects a U.S. total addressable market (TAM) of $25 to $33 billion across five initial indications for its SCD therapy, pending FDA approvals. These include: Pediatric and adult acute kidney injury (AKI) Cardiorenal syndrome Hepatorenal syndrome End-stage renal disease (ESRD) Systemic inflammatory response in cardiac surgery patients This TAM reflects the high unmet need in ICU settings and the potential for SCD to become a standard adjunct to continuous renal replacement therapy (CRRT).
0 · Reply
josh77
josh77 Oct. 25 at 3:27 AM
$ICU SeaStar’s Edge: Precision Targeting: Unlike broad-spectrum cytokine filters, SCD focuses on specific immune cells, offering a more tailored approach. Multiple Breakthrough Designations: SeaStar has received at least four FDA Breakthrough Device Designations, signaling strong regulatory support. Pediatric Focus: QUELIMMUNE therapy for pediatric AKI is a unique niche with high unmet need.
0 · Reply
josh77
josh77 Oct. 25 at 3:27 AM
$ICU SeaStar’s SCD therapy stands out for its cell-specific immune modulation, which could offer better outcomes with fewer side effects compared to more generalized blood purification systems.
0 · Reply
josh77
josh77 Oct. 25 at 3:26 AM
$ICU Comparison to Competitors SeaStar’s SCD therapy is part of a niche but growing field of immunomodulatory extracorporeal therapies. Here’s how it compares: Company / Therapy Mechanism Target Condition(s) Regulatory Status Differentiator SeaStar Medical (SCD) Cell-directed immune modulation AKI, Cardiorenal, ESRD, SIRS FDA Breakthrough Device (multiple) Targets activated neutrophils/monocytes CytoSorbents (CytoSorb) Hemoadsorption of cytokines Sepsis, Cardiac Surgery CE Mark, FDA Emergency Use Broad cytokine removal ExThera Medical (Seraph 100) Pathogen adsorption Sepsis, COVID-19 CE Mark, FDA Emergency Use Targets pathogens directly Toraymyxin Endotoxin adsorption Septic shock Approved in Japan, EU Specific to endotoxins
0 · Reply
josh77
josh77 Oct. 25 at 3:25 AM
$ICU QUELIMMUNE – Pediatric Acute Kidney Injury (AKI) Status: Approved under a Humanitarian Device Exemption (HDE) Launch: Commercially launched in July 2024 Designation: FDA Breakthrough Device Use: Treats critically ill children with AKI using SeaStar’s Selective Cytopheretic Device (SCD) therapy
0 · Reply
josh77
josh77 Oct. 25 at 3:25 AM
$ICU SCD Therapy – Adult Indications These indications use the same device with minimal modifications: Indication Status Acute Kidney Injury (AKI) Pivotal Trial Cardiorenal Syndrome Feasibility Study End-Stage Renal Disease (ESRD) Investigational Hepatorenal Syndrome (HRS) Investigational Systemic Inflammatory Response (Cardiac Surgery) Investigational
0 · Reply
josh77
josh77 Oct. 25 at 3:24 AM
$ICU Regulatory Acceleration Most pipeline products have received FDA Breakthrough Device Designation, which expedites development and review. SeaStar recently received two new Breakthrough Device Designations for treating systemic inflammatory response in adult and pediatric cardiac surgery patients
0 · Reply
josh77
josh77 Oct. 25 at 3:17 AM
$ICU Clinical Trial Results SeaStar recently reported positive early results for its QUELIMMUNE therapy in pediatric acute kidney injury (AKI) at the 5th International Symposium on AKI in Children. Upcoming data releases and trial updates—especially around 90-day survival rates and safety—could be pivotal
0 · Reply
josh77
josh77 Oct. 25 at 3:17 AM
$ICU FDA Regulatory Milestones The company’s Selective Cytopheretic Device (SCD) has Breakthrough Device Designation, which accelerates the FDA review process. Any movement toward FDA approval or expanded indications would be a major catalyst.
0 · Reply
josh77
josh77 Oct. 25 at 3:16 AM
$ICU Partnerships or Licensing Deals Any collaboration with larger medtech firms or hospitals could validate SeaStar’s technology and accelerate commercialization.
0 · Reply
josh77
josh77 Oct. 25 at 3:15 AM
$ICU The next earnings date is November 12, 2025. Investors will be watching for updates on: Cash runway Clinical progress Strategic outlook
0 · Reply
josh77
josh77 Oct. 25 at 3:14 AM
$ICU If all the above align, ICU could see a multi-bagger return, potentially trading in the $5$10 range or higher, depending on market sentiment and revenue projections.
0 · Reply